SCHEMBL6215499

SCHEMBL6215499

Fc1ccc(CNc2nc(Nc3ccc4[nH]cc(C5=CCNCC5)c4c3)ncc2Br)cc1F

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR6 P50406 2/20 0.39
▸ KDM4E B2RXH2 2/20 0.39
▸ ALDH1A1 P00352 2/20 0.39
▸ MAPT P10636 2/20 0.39
▸ HTR2C P28335 2/20 0.39
▸ HSD17B10 Q99714 2/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ CYP1A2 P05177 1/20 0.39
▸ CYP3A4 P08684 1/20 0.39
▸ HTR1D P28221 1/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ BRCA1 P38398 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ CCNT1 O60563 1/20 0.39
▸ CDK9 P50750 1/20 0.39
▸ NTRK1 P04629 2/20 0.39
▸ PTK2 Q05397 2/20 0.38
▸ CDK1 P06493 2/20 0.38
▸ JAK2 O60674 1/20 0.37
▸ PRKD3 O94806 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6239654 0.92 CDK1 (0.44) HTR6KDM4EALDH1A1MAPTHTR2C
SCHEMBL6212354 0.92 JAK2 (0.38) HTR6KDM4EALDH1A1MAPTHTR2C
SCHEMBL6236216 0.91 STK17B (0.42) HTR6KDM4EALDH1A1MAPTHTR2C
SCHEMBL6212597 0.90 NTRK1 (0.49) CCNT1CDK9NTRK1PTK2
SCHEMBL6210939 0.89 HTR2C (0.42) HTR6KDM4EALDH1A1MAPTHTR2C
SCHEMBL6212141 0.89 KDM4E (0.43) HTR6KDM4EALDH1A1MAPTHTR2C
SCHEMBL6210924 0.89 JAK2 (0.40) HTR6KDM4EALDH1A1MAPTHTR2C
SCHEMBL6211231 0.88 CDK1 (0.43) HTR6KDM4EALDH1A1MAPTHTR2C
SCHEMBL6209598 0.87 PTK2 (0.44) HTR6KDM4EALDH1A1MAPTHTR2C
SCHEMBL6211382 0.87 HTR6 (0.52) HTR6KDM4EALDH1A1MAPTHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1578732-A2 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH Pfizer Products Inc. (US) 2005-09-28 — — EP claimed
US-20040220177-A1 Compound for the treatment of abnormal cell growth PFIZER INC 2004-11-04 — — US claimed
WO-2004056786-A2 PYRIMIDINE DERIVATES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER PRODUCTS INC. (US) 2004-07-08 — — WO claimed
EP-1578732-A2 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH Pfizer Products Inc. (US) 2005-09-28 — — EP disclosed
US-20040220177-A1 Compound for the treatment of abnormal cell growth PFIZER INC 2004-11-04 — — US disclosed
WO-2004056786-A2 PYRIMIDINE DERIVATES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER PRODUCTS INC. (US) 2004-07-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220177-A1 Compound for the treatment of abnormal cell growth CCNA1, CCNB1, CCNT1 HTR6 3342/4885KDM4E 2081/4885ALDH1A1 218/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback